A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT ID: NCT06137183

Last Updated: 2025-06-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

79 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-01

Study Completion Date

2025-06-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study consists of two periods:

1. An induction period which will test the induction of clinical remission;
2. An optional active treatment extension (ATE) period which will explore durability of clinical response and remission in which all participants will receive vixarelimab.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vixarelimab Dose Regimen 1

Participants will receive vixarelimab subcutaneously (SC) during the induction period and the optional ATE period.

Group Type EXPERIMENTAL

Vixarelimab

Intervention Type DRUG

Vixarelimab will be administered as per the schedule specified in the respective arms.

Vixarelimab Dose Regimen 2

Participants will receive vixarelimab SC during the induction period and the optional ATE period.

Group Type EXPERIMENTAL

Vixarelimab

Intervention Type DRUG

Vixarelimab will be administered as per the schedule specified in the respective arms.

Placebo

Participants will receive placebo SC during the induction period and vixarelimab SC during the optional ATE period.

Group Type PLACEBO_COMPARATOR

Vixarelimab

Intervention Type DRUG

Vixarelimab will be administered as per the schedule specified in the respective arms.

Placebo

Intervention Type DRUG

Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vixarelimab

Vixarelimab will be administered as per the schedule specified in the respective arms.

Intervention Type DRUG

Placebo

Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RO7622888; KPL-716

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of UC for at least 3 months
* Moderately to severely active UC, assessed by mMS
* Inadequate response, loss of response to, or intolerance to conventional or advanced therapies for UC

Exclusion Criteria

* Diagnosis of Crohn's disease or indeterminate colitis
* Suspicion of ischemic, radiation, microscopic, or infectious colitis
* Prior colectomy
* Inadequate response or loss of response to previous treatment of UC with tofacitinib, upadacitinib, or other systemic janus kinase (JAK) inhibitor
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Genentech, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trial

Role: STUDY_DIRECTOR

Genentech, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gulf Coast Gatroenterology

Fairhope, Alabama, United States

Site Status

OM Research LLC - Camarillo - ClinEdge - PPDS

Camarillo, California, United States

Site Status

UCLA Clinical and Translational Research Center

Los Angeles, California, United States

Site Status

Facey Medical Foundation - Mission Hills

Mission Hills, California, United States

Site Status

Clinical Applications Laboratories, Inc.

San Diego, California, United States

Site Status

Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Site Status

Regenerate Primary Medical

Miami, Florida, United States

Site Status

Advanced Research Institute, Inc.

New Port Richey, Florida, United States

Site Status

Orlando Gastroenterology, P.A.

Orlando, Florida, United States

Site Status

Atlanta Gastroenterology Associates

Atlanta, Georgia, United States

Site Status

University of Chicago Medical Center

Chicago, Illinois, United States

Site Status

Henry Ford Health System

Novi, Michigan, United States

Site Status

Mayo Clinic - PPDS

Rochester, Minnesota, United States

Site Status

Delta Gastroenterology & Endoscopy Center

Southaven, Mississippi, United States

Site Status

Strong Memorial Hospital

Rochester, New York, United States

Site Status

Carolina Digestive Diseases

Greenville, North Carolina, United States

Site Status

Ohio Gastroenterology and Liver Institute

Cincinnati, Ohio, United States

Site Status

North Shore Gastroenterology

Westlake, Ohio, United States

Site Status

Tyler Research Institute, LLC

Tyler, Texas, United States

Site Status

University of Utah - Health Sciences Center - PPDS

Salt Lake City, Utah, United States

Site Status

CHU St Pierre (St Pierre)

Brussels, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

Cliagen Clinica de Atençao em Gastroenterologia, Especialidades e Nutriçao

Salvador, Estado de Bahia, Brazil

Site Status

L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME

Brasília, Federal District, Brazil

Site Status

Centro Digestivo de Curitiba

Curitiba, Paraná, Brazil

Site Status

Hospital de Clinicas de Porto Alegre HCPA PPDS

Pôrto Alegre, Pará, Brazil

Site Status

Associacao Hospitalar Moinhos de Vento

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital das Clinicas da Faculdade de Medicina de Botucatu (HCFMB)

Botucatu, São Paulo, Brazil

Site Status

Centro de Estudos Clinicos do Interior Paulista

Jaú, São Paulo, Brazil

Site Status

Pesquisare Saude

Santo André, São Paulo, Brazil

Site Status

Praxis Pesquisa Médica

Santo André, São Paulo, Brazil

Site Status

Kaiser Hospital Dia

São José do Rio Preto, São Paulo, Brazil

Site Status

Hospital Sirio-Libanes

São Paulo, São Paulo, Brazil

Site Status

Hospital Universitario Clementino Fraga Filho - UFRJ

Rio de Janeiro, , Brazil

Site Status

West China Hospital - Sichuan University

Chengdu, , China

Site Status

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, , China

Site Status

The Sixth Affiliated Hospital of Sun Yat-sen University

Guangzhou, , China

Site Status

Qilu Hospital of Shandong University

Jinan, , China

Site Status

Jinhua municipal central hospital

Jinhua, , China

Site Status

The First Affiliated Hospital of Nanchang University

Nanchang, , China

Site Status

The First Affiliated Hospital of Ningbo University(Ningbo First Hospital)

Ningbo, , China

Site Status

Shengjing Hospital of China Medical University

Shenyang, , China

Site Status

The Second Hospital of Hebei Medical University

Shijiazhuang, , China

Site Status

The First Affiliated Hospital of Soochow University

Suzhou, , China

Site Status

Tianjin Medical University General Hospital

Tianjin, , China

Site Status

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, , China

Site Status

Renmin Hospital of Wuhan University

Wuhan, , China

Site Status

Wuxi People's Hospital

Wuxi, , China

Site Status

General Hospital of Ningxia Medical University

Yinchuan, , China

Site Status

SurGal Clinic s.r.o.

Brno, , Czechia

Site Status

Hepato-Gastroenterologie HK, s.r.o.

Hradec Králové, , Czechia

Site Status

PreventaMed s.r.o.

Olomouc, , Czechia

Site Status

Endohope klinika s. r.o.

Prague, , Czechia

Site Status

CHU Nice - Hopital de l'Archet 2

Nice, , France

Site Status

Hospices Civils de Lyon Centre hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status

CHU de Saint-Etienne - Hopital Nord

Saint-Etienne, , France

Site Status

CHU de Nancy-Hopital Brabois Adulte

Vandœuvre-lès-Nancy, , France

Site Status

Charite - Campus Benjamin Franklin

Berlin, , Germany

Site Status

Universitaetsklinikum Halle (Saale)

Halle, , Germany

Site Status

Universitatsklinikum Schleswig-Holstein - Kiel

Kiel, , Germany

Site Status

Universitaetsklinikum Ulm

Ulm, , Germany

Site Status

Evangelismos General Hospital of Athens

Athens, Attica, Greece

Site Status

Sotiria General Hospital of Athens

Athens, , Greece

Site Status

Alexandra Hospital

Athens, , Greece

Site Status

University General Hospital of Heraklion

Heraklion, , Greece

Site Status

Iatriko Palaiou Falirou

Palaió Fáliro, , Greece

Site Status

Tzaneio General Hospital

Piraeus, , Greece

Site Status

Rambam Health Care Campus

Haifa, , Israel

Site Status

Meir Medical Center

Kfar Saba, , Israel

Site Status

Sheba Medical Center - PPDS

Ramat Gan, , Israel

Site Status

Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi-Via Massarenti

Bologna, Emilia-Romagna, Italy

Site Status

Fondazione Policlinico Universitario A Gemelli-Rome

Rome, Lazio, Italy

Site Status

Ospedale San Raffaele S.r.l. - PPDS

Milan, Lombardy, Italy

Site Status

Istituto Clinico Humanitas

Rozzano, Lombardy, Italy

Site Status

Azienda Ospedaliera Ordine Mauriziano di Torino

Turin, Piedmont, Italy

Site Status

Azienda Ospedaliero - Universitaria di Cagliari

Monserrato, Sardinia, Italy

Site Status

Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello

Palermo, Sicily, Italy

Site Status

IRCCS Ospedale Sacro Cuore Don Calabria

Negrar, Veneto, Italy

Site Status

Hospital Puerta de Hierro Sur

Tlajomulco de Zúñiga, Jalisco, Mexico

Site Status

Accelerium, S. de R.L. de C.V. - PPDS

Monterrey, Nuevo León, Mexico

Site Status

Medical Care & Research SA de CV

Mérida, Yucatán, Mexico

Site Status

Hospital Angeles Chihuahua

Chihuahua City, , Mexico

Site Status

Melita Medical Sp. Z O. O.

Wroclaw, Lower Silesian Voivodeship, Poland

Site Status

EuroMediCare Szpital Specjalistyczny z Przychodni? we Wroc?awiu

Wroclaw, Lower Silesian Voivodeship, Poland

Site Status

Clinical Trials UMED Sp. z o. o.

?ód?, , Poland

Site Status

Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi sp. z o.o.

?ód?, , Poland

Site Status

Medical Center Kermed

Bydgoszcz, , Poland

Site Status

Polimedica PTG Kielce

Kielce, , Poland

Site Status

MZ Badania Slowik Zymla Sp.j.

Knurów, , Poland

Site Status

Topolowa Medicenter Mrozek & Wspolnicy Spolka Jawna

Krakow, , Poland

Site Status

Allmedica Badania Kliniczne sp. z o.o. sp.k.

Nowy Targ, , Poland

Site Status

Office of Jaroslaw Kierkus, Dr n Med

Otwock, , Poland

Site Status

Endoskopia Sp. z o.o.

Sopot, , Poland

Site Status

Sonomed Sp. z o.o.

Szczecin, , Poland

Site Status

Centrum Medyczne UNO-MED-Tarnow

Tarnów, , Poland

Site Status

NZOZ FORMED sp zo.o.

Wadowice, , Poland

Site Status

Centrum Zdrowia MDM

Warsaw, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED

Warsaw, , Poland

Site Status

PlanetMed

Wroc?aw, , Poland

Site Status

Przychodnia VISTAMED

Wroc?aw, , Poland

Site Status

Clinical Hospital Center Dragisa Misovic Dedinje

Belgrade, , Serbia

Site Status

Military Medical Academy

Belgrade, , Serbia

Site Status

Clinical Hospital Center Bezanijska Kosa

Beograd-zemun, , Serbia

Site Status

Clinical Center Kragujevac

Kragujevac, , Serbia

Site Status

Clinical Centre of Vojvodina

Nova Sad, , Serbia

Site Status

General Hospital Djordje Joanovic - Zrenjanin

Zrenjanin, , Serbia

Site Status

Inje university Haeundae Paik Hospital

Busan, , South Korea

Site Status

Kosin University Gospel Hospital

Busan, , South Korea

Site Status

Kyungpook National University Hospital

Daegu, , South Korea

Site Status

The Catholic University of Korea Daejeon ST. Mary?s Hospital

Daejeon, , South Korea

Site Status

Yonsei University Wonju Severance Christian Hospital

Gangwon-do, , South Korea

Site Status

Kangbuk Samsung Hospital

Seoul, , South Korea

Site Status

Severance Hospital Yonsei University Health System - PPDS

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

E-Da Hospital

Kaohsiung City, , Taiwan

Site Status

Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital

Niaosong Dist., , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

The Royal London Hospital

London, , United Kingdom

Site Status

Hammersmith Hospital

London, , United Kingdom

Site Status

John Radcliffe Hospital

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Brazil China Czechia France Germany Greece Israel Italy Mexico Poland Serbia South Korea Taiwan United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-506655-19-00

Identifier Type: CTIS

Identifier Source: secondary_id

GA44839

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.